Chia Tai Tianqing’s TQ-B3525 Heads for Priority Review for Recurrent Follicular Lymphoma
The Center for Drug Evaluation (CDE) website has indicated that Chia Tai Tianqing’s TQ-B3525, a...
Sanofi Launches Soliqua for Type 2 Diabetes Treatment in China
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced the official market launch of Soliqua (insulin...
GenScript’s Legend Biotech Files Type II Variation Application for Carvykti with EMA
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...
Takeda and HutchMed’s Fruquintinib Receives Priority Review Status from FDA
Takeda (TYO: 4502) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) have provided an update...
China’s NHC Releases Fourth List of Pediatric Priority Drugs to Boost Development
The National Health Commission (NHC) of China has published its fourth list of pediatric drugs...
Sichuan Kelun Pharmaceutical to Present Clinical Data on RET Inhibitor and ADC at ASCO
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a China-based pharmaceutical company, has unveiled plans to...
Lancet Study Reveals Dalian’s Cancer Survival Rates Compared to US
A recent study published in The Lancet has conducted a comparative analysis of cancer mortality...
BioRay Pharmaceutical’s LIV-1 Targeted ADC BRY812 Files IND in China
Shanghai-based BioRay Pharmaceutical Co., Ltd has announced that an investigational new drug (IND) filing has...
Accropeutics Receives HREC Approval for AC-201 Phase I Trial
Suzhou-based Accro Bioscience (Suzhou) Limited (Accropeutics) has announced that it has received approval from the...
Vcanbio Initiates Phase II Clinical Study for Dental Pulp Stem Cell Injection in Periodontitis
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced the imminent initiation...
Mabwell Bioscience’s 9MW3811 Receives NMPA Approval for Clinical Trials in Oncology and Fibrosis
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical...
Roche’s Rozlytrek on Track for Priority Review for Pediatric NTRK Fusion Tumor Treatment
The Center for Drug Evaluation (CDE) website has indicated that Roche’s (SWX: ROG) Rozlytrek (entrectinib)...
Zelixir Biotech Secures Over RMB 100 Million in Series A Financing for Synthetic Biology Pipeline
Shanghai-based Zelixir Biotech, a leading provider of protein structure prediction and design services, has reportedly...
PathoAI Secures Tens of Millions in Angel Financing for AI-Powered Pathology Solutions
PathoAI, a company at the forefront of intelligent pathology and examination through artificial intelligence (AI),...
Asieris Pharmaceuticals to Present Phase I Results of APL-1202 Combo at ASCO
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced that it will publish the...
MicroPort Endovascular MedTech Announces Private Placement to Fund Innovation and Expansion
China-based Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has announced plans to raise up...
Antengene’s ATG-022 Earns FDA Orphan Drug Designations for Gastric and Pancreatic Cancers
China-based Antengene Corporation Limited (HKG: 6996) has announced that its in-house discovered and developed antibody...
CDE Drafts Proposal on Generic Drug Studies for Varieties without Reference Preparations
The Center for Drug Evaluation (CDE) has released a Notice on the “Generic Study for...
Mural Health Partners with Clinflash to Enhance Patient Payments in Clinical Trials
US-based Mural Health has announced a strategic partnership with China-based Clinflash, both companies specializing in...
Hanx Biopharmaceuticals’ HX009 Receives US IND Approval for Lymphoma Treatment
Wuhan-based firm Hanx Biopharmaceuticals Inc. has announced the receipt of an Investigational New Drug (IND)...